Skip to main content

Table 1 Main characteristics of all the studies included in the meta-analysis

From: Meta-analysis of associations between neutrophil-to-lymphocyte ratio and prognosis of gastric cancer

First author Publish time Age (years) Number of patients; stage of TNM Treatment arm NLR cutoff (HNLR/LNLR) Follow-up (months) (median and range) Study quality
Lee S 2013 55 ± 12.4a 7/22/41/104; I to IV Palliative/adjuvant chemotherapy 3 (62/112) 14.9 (1.0 to 47.9)b 6
Lee DY 2013 57 (23 to 89)b 110/35/62/3; I to IV Adjuvant chemotherapy 2.15 (50/164) NR 5
Jin H 2013 60 (37 to 77)b 36/8; III to IV Neoadjuvant chemotherapy 2.5 (24/22) NR 5
Dirican A 2013 58 (30 to 86)b 6/20/105/105; I to IV Palliative/adjuvant chemotherapy 3.8 (89/147) 60 5
Wang DS 2012 <65/230 ≥ 65/94 324; III Adjuvant chemotherapy 5 (156/168) 39.9 (23.77 to 57.43)b 6
Jeong JH 2012 52.5 (28 to 82)b 104; IV Palliative chemotherapy 3 (55/49) 11.9 (10.2 to 13.5)b 6
Mohri Y 2010 63.4 (32 to 87)b 232/57/68; I to III Adjuvant chemotherapy/ neoadjuvant chemotherapy 2.2 (130/227) 68 (1 to 70)b 5
Shimada H 2010 65 (26 to 89)b 584/132/153/159; I to IV Adjuvant chemotherapy 4 (127/901) 23 (12 to 84)b 5
Yamanaka T 2007 <60/493 ≥ 60/727 1220; IV Palliative chemotherapy 2.5 (664/576) 15.6 6
  1. NLR, neutrophil-to-lymphocyte ratio; HNLR, high pretreatment NLR; LNLR, low pretreatment NLR; NA, not applicable. aData as mean ± SD. bData as mean (range).